Detecting lung diseases early after stem cell transplants

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to improve the early detection of lung inflammation and injury in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Researchers will utilize preemptive pulmonary imaging and biomarker measurements through surveillance bronchoscopy to identify early signs of lung issues. Participants aged 5 to 70 will undergo tests before and regularly after their HSCT for two years, including ultra-low dose CT scans and bronchoalveolar lavage. The goal is to enhance the identification of patients at risk for lung diseases and facilitate the development of targeted therapies.

Why it matters

Who can join: the full rules

* INCLUSION CRITERIA:

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

1. Stated willingness to comply with all study procedures and availability for the duration of the study.
2. Male or female, aged 5 - 70 years of age
3. Are to be treated with allogeneic HSCT for a hematologic malignancy, blood, or immune system disorders at the NIH Clinical Center.
4. Ability of subject to understand and the willingness to sign a written informed consent document.

EXCLUSION CRITERIA:

An individual who meets any of the following criteria will be excluded from participation in this study:

1\. Pregnancy or lactation

a. HSCT is not available to pregnant women or lactating women in the intramural program. For women of reproductive potential, have a negative serum pregnancy test during the screening period. Women of reproductive potential are defined as sexually mature women who have not undergone a hysterectomy, bilateral oophorectomy, or tubal occlusion; or who have not been naturally postmenopausal (i.e., who have not menstruated at all for at least the preceding 1 year prior to signing informed consent unrelated to hormonal contraception).

Where it's running

• National Institutes of Health Clinical Center
  Bethesda, Maryland, United States Recruiting

Study contacts

• Principal investigator: Anthony F Suffredini, M.D. — National Heart, Lung, and Blood Institute (NHLBI)
• Study coordinator: Gloria Y Pastor, C.R.N.P.
• Email: pastorg@cc.nih.gov
• Phone: (301) 402-3484

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Tracking invasive fungal infections after allogeneic hematopoietic stem cell transplant

  We will follow people who had an allogeneic stem cell transplant to see how often serious fungal infections occur and which clinical factors predict them.

  Recruiting Peking University People's Hospital · Beijing, Beijing Municipality · NCT07569055

• Ruxolitinib plus decitabine intensified conditioning for AML patients having allogeneic stem cell transplant

  This trial will see if adding ruxolitinib and decitabine to standard busulfan-based conditioning before allogeneic HSCT lowers relapse in high‑risk AML patients in first complete remission (CR1).

  Recruiting Phase 4 Chinese PLA General Hospital · Beijing, Beijing Municipality · NCT07101588

• VLCPUFA-rich fish oil and standard DHA oil: who reaches a higher omega-3 index?

  This study tests whether VLCPUFA-rich fish oil raises the blood omega-3 index more than a standard DHA-rich fish oil in healthy adults aged 18–60.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07882160

• Blood biomarkers for immune-related neuropsychiatric conditions

  This study tests whether blood biomarkers can help identify neuropsychiatric disorders that may be linked to the immune system in people of any age.

  Recruiting at 3 sites National Institutes of Health Clinical Center (CC) · Los Angeles, California and 2 other locations · NCT07877246

• First-in-human imaging of PDE4D with [11C]JMJ-129-d2 in healthy volunteers

  A new PET tracer called [11C]JMJ-129-d2 is being tested in healthy adults to see if it safely and reliably images the brain’s PDE4D enzyme and to measure how the tracer distributes in the body.

  Recruiting Phase 1 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07853781

• Pain patterns in rheumatic diseases: see if pain works differently in patients and healthy people

  This observational study tests how pain is experienced and measured in people with rheumatic diseases compared with healthy volunteers.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07829497

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.